Literature DB >> 21844812

Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling.

Grace Wang1, Mary S Beattie, Ninez A Ponce, Kathryn A Phillips.   

Abstract

PURPOSE: : Coverage policies for genetic services for hereditary cancers are of interest because the services influence cancer risk reduction for both persons with cancer and their family members. We compared coverage policies for BRCA genetic testing and genetic counseling among selected payers in the United States to illuminate eligibility criteria variation that may explain differential access by insurance type. We compared these policies with policies for breast cancer screening with magnetic resonance imaging to consider whether payers apply a unique policy approach to genetic services.
METHODS: : We conducted a case study of large private and public payers selected on number of covered lives. We examined coverage policies for BRCA genetic testing, genetic counseling, and screening with magnetic resonance imaging and the eligibility criteria for each. We compared eligibility criteria against National Comprehensive Cancer Network guidelines.
RESULTS: : Eligibility criteria for BRCA testing were related to personal history and family history of cancer. Although private payers covered BRCA testing for persons with and without cancer, the local Medicare carrier in our study only covered testing for persons with cancer. In contrast, Arizona's Medicaid program did not cover BRCA testing. Few payers had detailed eligibility criteria for genetic counseling. Private payers have more detailed coverage policies for both genetic services and screening with magnetic resonance imaging in comparison with public payers.
CONCLUSION: : Despite clinical guidelines establishing standards for BRCA testing, we found differences in coverage policies particularly between private and public payers. Future research and policy discussions can consider how differences in private and public payer policies influence access to genetic technologies and health outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844812      PMCID: PMC4537294          DOI: 10.1097/GIM.0b013e31822a8113

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  25 in total

1.  Economic considerations for health insurance coverage of emerging genetic tests.

Authors:  Mita Giacomini; Fiona Miller; Bernie J O'Brien
Journal:  Community Genet       Date:  2003

2.  Genetic testing coverage and reimbursement: a provider's dilemma.

Authors:  L Joan Logue
Journal:  Clin Leadersh Manag Rev       Date:  2003 Nov-Dec

3.  Cost-effectiveness and evidence evaluation as criteria for coverage policy.

Authors:  Alan M Garber
Journal:  Health Aff (Millwood)       Date:  2004 Jan-Jun       Impact factor: 6.301

4.  Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests.

Authors:  Scott D Ramsey; David L Veenstra; Louis P Garrison; Rick Carlson; Paul Billings; Josh Carlson; Sean D Sullivan
Journal:  Am J Manag Care       Date:  2006-04       Impact factor: 2.229

5.  Comparison between US Preventive Services Task Force recommendations and Medicare coverage.

Authors:  Lenard I Lesser; Alex H Krist; Douglas B Kamerow; Andrew W Bazemore
Journal:  Ann Fam Med       Date:  2011 Jan-Feb       Impact factor: 5.166

6.  Cancer risk assessment: examining the family physician's role.

Authors:  Carl V Tyler; Clint W Snyder
Journal:  J Am Board Fam Med       Date:  2006 Sep-Oct       Impact factor: 2.657

7.  Factors influencing health insurers' decisions to cover new genetic technologies.

Authors:  M M Schoonmaker; B A Bernhardt; N A Holtzman
Journal:  Int J Technol Assess Health Care       Date:  2000       Impact factor: 2.188

8.  When family means more (or less) than genetics: the intersection of culture, family and genomics.

Authors:  Barbara Burns McGrath; Karen L Edwards
Journal:  J Transcult Nurs       Date:  2009-07       Impact factor: 1.959

9.  The role of financial factors in acceptance of clinical BRCA genetic testing.

Authors:  Shannon Kieran; Lois J Loescher; Kyung Hee Lim
Journal:  Genet Test       Date:  2007

Review 10.  Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors.

Authors:  Janice L Berliner; Angela Musial Fay
Journal:  J Genet Couns       Date:  2007-05-17       Impact factor: 2.717

View more
  22 in total

1.  Using Public-Private Partnerships to Mitigate Disparities in Access to Genetic Services: Lessons from Wisconsin.

Authors:  Laura Senier; Matthew Kearney; Jason Orne
Journal:  Adv Med Sociol       Date:  2015

2.  An investigation of genetic counselors' testing recommendations: pedigree analysis and the use of multiplex breast cancer panel testing.

Authors:  Meghan G Lundy; Andrea Forman; Kathleen Valverde; Lisa Kessler
Journal:  J Genet Couns       Date:  2014-02-27       Impact factor: 2.537

3.  Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.

Authors:  Julia R Trosman; Christine B Weldon; Michael P Douglas; Allison W Kurian; R Kate Kelley; Patricia A Deverka; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2017-02-10       Impact factor: 11.908

4.  Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.

Authors:  Yaojen Chang; Aimee M Near; Karin M Butler; Amanda Hoeffken; Sandra L Edwards; Antoinette M Stroup; Wendy Kohlmann; Amanda Gammon; Saundra S Buys; Marc D Schwartz; Beth N Peshkin; Anita Y Kinney; Jeanne S Mandelblatt; Yaojen Chang; Aimee M Near; Karin M Butler; Amanda Hoeffken; Sandra L Edwards; Antoinette M Stroup; Wendy Kohlmann; Amanda Gammon; Saundra S Buys; Marc D Schwartz; Beth N Peshkin; Anita Y Kinney; Jeanne S Mandelblatt
Journal:  J Oncol Pract       Date:  2016-01       Impact factor: 3.840

5.  Exploring barriers to payer utilization of genetic counselors.

Authors:  Nan Doyle; Allison Cirino; Amber Trivedi; Maureen Flynn
Journal:  J Genet Couns       Date:  2014-08-20       Impact factor: 2.537

Review 6.  Coverage of Intravenous Immunoglobulin for Autoimmune Blistering Diseases Among US Insurers.

Authors:  Manuel Valdebran; Kyle T Amber
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

7.  Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.

Authors:  Margaret I Liang; Deanna H Wong; Christine S Walsh; Robin Farias-Eisner; Joshua G Cohen
Journal:  J Genet Couns       Date:  2017-08-07       Impact factor: 2.537

8.  Development of a Streamlined Work Flow for Handling Patients' Genetic Testing Insurance Authorizations.

Authors:  Wendy R Uhlmann; Katie Schwalm; Victoria M Raymond
Journal:  J Genet Couns       Date:  2017-04-24       Impact factor: 2.537

9.  Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.

Authors:  Priyanka Sharma; Jennifer R Klemp; Bruce F Kimler; Jonathan D Mahnken; Larry J Geier; Qamar J Khan; Manana Elia; Carol S Connor; Marilee K McGinness; Joshua M W Mammen; Jamie L Wagner; Claire Ward; Lori Ranallo; Catherine J Knight; Shane R Stecklein; Roy A Jensen; Carol J Fabian; Andrew K Godwin
Journal:  Breast Cancer Res Treat       Date:  2014-05-07       Impact factor: 4.872

10.  Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.

Authors:  Anne Marie McCarthy; Mirar Bristol; Tracey Fredricks; Lache Wilkins; Irene Roelfsema; Kaijun Liao; Judy A Shea; Peter Groeneveld; Susan M Domchek; Katrina Armstrong
Journal:  Cancer       Date:  2013-07-16       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.